BLOCK-iT™ Lentiviral RNAi Zeo Gateway™ Vector Kit
Product Image
Invitrogen™

BLOCK-iT™ Lentiviral RNAi Zeo Gateway™ Vector Kit

The BLOCK-iT™ Lentiviral RNAi Zeo Gateway™ Vector Kit contains the pLenti4/BLOCK-iT™-DEST expression vector which enables lentiviral delivery and genomic integrationRead more
Have Questions?
Catalog NumberQuantity
V48820
also known as V488-20
20 Reactions
Catalog number V48820
also known as V488-20
Price (CNY)
28,611.00
20 reactions
Add to cart
Quantity:
20 Reactions
Price (CNY)
28,611.00
20 reactions
Add to cart
The BLOCK-iT™ Lentiviral RNAi Zeo Gateway™ Vector Kit contains the pLenti4/BLOCK-iT™-DEST expression vector which enables lentiviral delivery and genomic integration of DNA coding for shRNA. Once expressed, the shRNA is processed by cellular machinery and initiates target-specific RNAi. The pLenti4/BLOCK-iT™-DEST vector offers:

Gateway™ Technology for efficient recombination of the RNAi cassette from the BLOCK-iT™ inducible pENTR™/H1/TO vector

• All required components for efficient lentiviral packaging, delivery, and integration of the shRNA
• Zeocin™ selection marker for fast selection of clonal cell lines containing the RNAi cassette
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Cloning MethodGateway™
Constitutive or Inducible SystemInducible
Delivery TypeLentiviral
Product LineBLOCK-iT™, Gateway™
Product TypeRNAi Expression Vector Kit
Quantity20 Reactions
RNAi TypeshRNA
Selection Agent (Eukaryotic)Zeocin™
VectorpLenti
FormatKit
PromoterH1/TO
Unit Size20 reactions
Contents & Storage
The BLOCK-iT™ Lentiviral RNAi Zeo Gateway™ Vector Kit contains the pLenti4/BLOCK-iT™-DEST vector, pLenti4-GW/H1/TO-lamin shRNA control vector, and One Shot™ Stbl3™ Chemically Competent E.Coli. Store the pLenti4/BLOCK-iT™-DEST, pLenti6/TR vector, Blasticidin, ViraPower™ Lentiviral packaging mix, and the control vector at -20°C. Store the One Shot Stbl3™ Competent Cells 293 FT cell, and LR Clonase™ enzyme mix at -80°C. Store Lipofectamine™ 2000 at +4°C. All reagents are guaranteed stable for 6 months when properly stored.

Frequently asked questions (FAQs)

Can I use any Gateway entry vector to generate entry clones for use in RNAi applications?

No, you should use an entry vector that contains the elements necessary for RNA Polymerase III-dependent expression of your shRNA (i.e., Pol III promoter and terminator).

What is a dose response curve or kill curve? And can you outline the steps involved?

A dose response curve or kill curve is a simple method for determining the optimal antibiotic concentration to use when establishing a stable cell line. Untransfected cells are grown in a medium containing antibiotic at varying concentrations in order to determine the lowest amount of antibiotic needed to achieve complete cell death. The basic steps for performing a dose response curve or kill curve are as follows:

- Plate untransfected cells at 25% confluence, and grow them in a medium containing increasing concentrations of the antibiotic. For some antibiotics, you will need to calculate the amount of active drug to control for lot variation.
- Replenish the selective medium every 3-4 days. After 10-12 days, examine the dishes for viable cells. The cells may divide once or twice in the selective medium before cell death begins to occur.
- Look for the minimum concentration of antibiotic that resulted in complete cell death. This is the optimal antibiotic concentration to use for stable selection.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

Can I create stable cell lines using pENTR/U6 entry vector or the pENTR/H1/TO vector?

Unfortunately, the pENTR/U6 vector does not contain a selection marker; therefore, only transient RNAi analysis may be performed. If you wish to generate stable cell lines, perform an LR reaction into an appropriate Gateway destination vector to generate expression clones.
The pENTR/H1/TO vector contains the Zeocin resistance gene to facilitate generation of cell lines that inducbily express the shRNA of interest. Perform a kill curve to determine the minimum concentration of Zeocin that is required to kill your untransfected mammalian cell line. Please note that Zeocin-sensitive cells do not round up and detach from the plate, but rather may increase in size, show abnormal cell shape, display presence of large empty vesicles in the cytoplasm, or show breakdown of plasma/nuclear membranes.

Find additional tips, troubleshooting help, and resources within our RNAi Support Center.

What loop sequence should I use when designing my shRNA for cloning? Do you have any guidelines I should follow?

You can use a loop sequence of any length ranging from 4 to 11 nucleotides, although short loops (i.e., 4-7 nucleotides) are generally preferred. Avoid using a loop sequence containing thymidines (Ts), as they may cause early termination. This is particularly true if the target sequence itself ends in one or more T nucleotides. Here are some loop sequences we recommend:

- 5' - CGAA - 3'
- 5' - AACG - 3'
- 5' - GAGA - 3'

What considerations regarding transcription initiation should I take when designing my shRNA for cloning?

Transcription of the shRNA initiates at the first base following the end of the U6 promoter sequence. In the top-strand oligo, the transcription initiation site corresponds to the first nucleotide following the 4 bp CACC sequence added to permit directional cloning. We recommend initiating the shRNA sequence at a guanosine (G) because transcription of the native U6 snRNA initiates at a G. Note the following:

- If G is part of the target sequence, then incorporate the G into the stem sequence in the top-strand oligo and add a complementary C to the 3' end of the top-strand oligo.
- If G is not the first base of the target sequence, we recommend adding a G to the 5' end of the top-strand oligo directly following the CACC overhang sequence. In this case, do not add the complementary C to the 3' end of the top-strand oligo. Note: We have found that adding the complementary C in this situation can result in reduced activity of the shRNA. Alternative, if use of a G to initiate transcription is not desired, use an adenosine (A) rather than C or T. Note, however, that use of any nucleotide other than G may affect initiation efficiency and position.